Dr. Mary Claire Haver: Birth Control & Menopause Guide

Feb 19, 2025

Birth Control Options and Their Effects on Menopause

Birth control remains one of the most debated topics in women’s health, with various options available and different effects on the body’s natural processes. Let’s explore the science behind these methods and their relationship to menopause.

The fundamental approaches to birth control can be broken down into three primary mechanisms: blocking sperm, preventing ovulation, or interrupting the communication between sperm and egg in the fallopian tube. While various options exist, Haver argues that vasectomy is the most effective form of birth control, noting that contraceptive responsibility often disproportionately falls on women.

Hormonal contraception works by suppressing ovulation through various delivery methods – pills, patches, or rings. Each format carries its own risk-benefit profile. For instance, transdermal applications show lower blood clot risks compared to oral contraceptives. IUDs function differently, creating an inflammatory environment in the uterus and forming a cervical plug to prevent sperm passage.

Progesterone-coated IUDs offer an interesting benefit: they can thin the uterine lining to the point of stopping menstruation while maintaining natural ovulation cycles. This provides convenience without completely disrupting the body’s natural processes.

A common concern is how birth control affects the timing of menopause. According to Haver, long-term use of ovulation-suppressing contraceptives may delay menopause by approximately nine months to a year. This delay occurs because natural ovulation involves losing about 11,000 eggs per cycle to produce one viable egg. When ovulation is suppressed, this natural loss is prevented.

For those considering egg freezing, Huberman and Haver emphasize an important point: harvesting eggs for freezing or IVF does not accelerate the onset of menopause. The process typically retrieves 10-12 eggs per cycle, which is minimal compared to the natural monthly loss of 11,000 eggs during ovulation.

The relationship between birth control and reproductive health demonstrates the complex interplay between medical intervention and natural biological processes. Understanding these interactions helps women make more informed decisions about their reproductive health.

Birth Control Methods and Menopause Research Funding

The stark reality of women’s health research funding reveals a troubling gap in our medical knowledge. The numbers tell a clear story: while women’s health receives only a small fraction of NIH funding, menopause research gets an even smaller slice – a mere 0.03%. This is particularly alarming considering menopause affects one-third of a woman’s life.

A recent McKinsey & Company analysis of 680 studies on chronic diseases highlights another concerning trend. Only half of these studies bothered to analyze sex-specific differences in their results. Among those that did, 30% of women experienced poorer outcomes compared to just 10% of men. These statistics underscore a systemic blind spot in medical research.

The landscape of birth control understanding is equally murky. Haver points out that certain methods, like the copper IUD, which creates an unfavorable environment for sperm without disrupting ovulation, don’t affect the timing of perimenopause or menopause. However, hormonal birth control methods can potentially extend the window of fertility by delaying these transitions.

Recent legislative efforts have begun to address these gaps. A $100 million initiative for women’s health research was recently signed into law, though this funding must be divided among various conditions including endometriosis, PCOS, and menopause research. Another proposed bill would allocate $250 million and includes provisions for provider education – a critical need given the generational gap in menopause education following the Women’s Health Initiative study.

Huberman suggests a straightforward path to advocacy: contact your representatives. While government processes move slowly, public pressure can influence research funding priorities. Historical examples, like the Brain Initiative, demonstrate how grassroots advocacy can lead to significant research funding allocation.

The current state of women’s health research presents a paradox: women are living longer than men, yet spending 20-25% of their lives in poorer health. This disparity demands attention, funding, and a fundamental shift in how we approach sex-specific differences in medical research and treatment.

OB-GYN Training and Research Gaps in Menopause Care

The state of menopause care and research in modern medicine reveals a troubling disconnect between medical education and women’s health needs. Despite the critical importance of managing menopausal symptoms and understanding hormone replacement therapy (HRT), there exists a significant knowledge gap among OB-GYNs.

The American Board of Obstetrics and Gynecology’s approach to continuing education exemplifies this problem. Their board certification process, which should keep physicians updated on the latest medical advances, notably excludes menopause as a distinct category. A review of professional journals over the past decade shows that less than 1% of articles address menopause-related topics.

This systemic oversight has created a generation of physicians who, while expertly trained in areas like childbirth and pediatric gynecology, lack comprehensive knowledge about caring for women in their post-reproductive years. The implications of this gap extend beyond individual patient care to shape broader medical perspectives and treatment protocols.

The infamous Watergate Hotel study on hormone replacement therapy, which has significantly influenced medical practice, demonstrates how flawed research design can impact treatment decisions. By studying women who began HRT at age 61, rather than at the onset of menopause, the study failed to capture the protective benefits of early intervention.

More progressive research is emerging from unexpected quarters. Asian countries, particularly China, are producing groundbreaking studies in women’s health. This may be attributed to their more egalitarian research environment, where female researchers participate equally in medical science. Similarly, Scandinavian countries have contributed valuable data supporting the protective benefits of appropriately timed hormone therapy.

The medical establishment must recognize that proficiency in managing pregnancy and surgical procedures, while crucial, is insufficient for comprehensive women’s healthcare. The future of menopause care depends on addressing these educational and research gaps, ensuring that physicians are equipped to support women through all life stages.

PCOS Causes and Treatment Options

Polycystic ovarian syndrome (PCOS) has emerged as a prominent health concern, with its increasing prevalence tied to multiple factors. According to Haver, the obesity epidemic has significantly contributed to the rise in PCOS cases, as insulin resistance often underlies the condition’s pathophysiology. However, it’s crucial to note that PCOS isn’t exclusively linked to obesity.

The condition can manifest in various ways, even in individuals maintaining healthy body weight. Haver’s personal experience as a thin PCOS sufferer demonstrates this complexity. Her case went undiagnosed for years, initially dismissed as medical student stress, until insulin resistance was identified as the root cause.

Treatment approaches for PCOS have evolved over time. Traditional methods focused on birth control to suppress ovulation and reduce androgen production. However, weight management has proven effective, particularly for patients carrying excess weight. The emergence of GLP1 agonists has introduced a new dimension to PCOS treatment, with many patients experiencing restored ovulation and normalized menstrual cycles.

The connection between GLP1 agonists and fertility has created unexpected outcomes. Haver notes a surge in pregnancies among patients using medications like Ozempic and Mounjaro, similar to the pattern observed following gastric bypass surgeries. This development necessitates careful counseling about contraception for women who aren’t planning pregnancy.

The implementation of GLP1 agonists requires a comprehensive approach. Haver emphasizes the importance of proper medical supervision and long-term health planning. Patients need guidance on maintaining muscle mass through adequate protein intake and resistance training. Notably, women combining hormone replacement therapy with GLP1 agonists have shown a 30% increase in weight loss effectiveness.

These medications’ impact extends beyond weight management. Research indicates their potential to reduce various reward-seeking behaviors, including alcohol consumption, gambling, and gaming. This broader effect pattern suggests complex interactions within the hypothalamus, where multiple drive-related neurons interconnect.

The medical community anticipates continued evolution in this field. Obesity medicine specialists predict improvements in medication profiles with reduced side effects, comparing the progression to smartphone development. As research funding pours into this sector, new iterations of these medications may offer enhanced benefits with minimized drawbacks.

Read Andrew Huberman

Discussion about this post